Introduction: Inherited antithrombin (AT) deficiency is a heterogeneous disease. Due to low prevalence, only a few studies are available concerning genotype-phenotype associations. The aim was to describe the clinical, laboratory and genetic characteristics of AT deficiency in a large cohort including children and to add further laboratory data on the different sensitivity of functional AT assays.
Introduction
Thrombosis is highly frequent in the developed countries and considered as major determinant of morbidity and mortality [1] . Antithrombin (AT) belongs to the serpin superfamily and regulates coagulation by inhibiting thrombin, activated factor X (FXa), and to a lesser extent FIXa, FXIa, FXIIa and FVIIa [2, 3] . Hereditary AT deficiency is classified as type I (quantitative) and type II (qualitative) [4] . In type II deficiency, the defect may affect the reactive site (IIRS), the heparin-binding site (IIHBS) or it can exert pleiotropic effect (IIPE). In general, the complete absence of AT is incompatible with life; in most cases (except for IIHBS) heterozygosity is associated with severe thrombotic symptoms. In IIHBS deficiency homozygosity may be compatible with life, however, those patients suffer from severe thrombosis. The thrombotic risk of heterozygote IIHBS patients is suggested to be less severe than other heterozygotes [5, 6] . In addition to venous thrombosis (VTE), occasionally, arterial thrombotic events (ATE) were also described in AT deficiency [7] [8] [9] [10] [11] [12] .
The human AT gene (SERPINC1) is localized on chromosome 1q23-25, consists of 7 exons and 6 introns and encodes 464 amino acids [5] . The mutation profile of SERPINC1 is heterogeneous, more than 310 different mutations have been reported (http://www.hgmd.cf.ac.uk; last accessed at August 28, 2017). Missense mutations are the most frequent, but nonsense and splice-site mutations, insertions and deletions may also occur. Genetic analysis is a useful diagnostic tool for confirming inherited AT deficiencies, especially for patients with borderline AT activity values [13] . The mutation detection rate in SERPINC1 in patients with decreased AT activity is variable among different populations; in general it is 69-83% Measurement of AT activity in the absence of heparin (progressive AT activity, panti-FXa) is useful for discriminating between IIHBS and other types [22] . The sensitivity of functional assays is various [10, 12, 23] . FXa-based assays are thought to be less sensitive for certain variants around the reactive site, like AT Cambridge II [17, 18] . In contrast, it was published that hc-anti-FXa assays had higher sensitivity to type IIHBS AT deficiency, than hc-anti-IIa assays [12, 24, 25 ]. An algorithm for laboratory diagnosis of AT deficiency was established, which is based on the determination of hc-anti-FXa, p-anti-FXa, AT antigen and molecular genetic testing The aim of the present study was to describe and compare the clinical and laboratory characteristics of different types of AT deficiency in a large cohort of patients including a large group of children; to explore the genetic background, to describe novel mutations, to define the mutation detection rate in patients with decreased AT levels in a tertiary diagnostic center and to add further laboratory data on the sensitivity of functional AT assays. 6
Patients and Methods

Patients
Patients with thromboembolic history and/or pregnancy complications (please see later in details) and reduced hc-anti-FXa AT activity determined from at least two independent blood samples were selected for our study. 156 non-related AT deficient patients (index patients) and their family members (total n=246) were diagnosed at our center.
All enrolled individuals were informed about the study according to the study protocol, and gave written informed consent. Ethical approval for the study was obtained from the National Ethical Council (3166/2012/HER). 
Laboratory methods
Molecular genetic analysis of SERPINC1
Genomic DNA was isolated from peripheral whole blood by using the QIAamp DNA 
In silico prediction of novel missense mutations
The pathogenicity of the novel mutations were evaluated by three prediction methods, [34] . The PolyPhen2 server offers two (HumDiv and HumVar)
scoring schemes, which differ in the training sets on which they were developed [30] .
For all the applied methods the score values between 0.5-1.0 mean possibly/probably pathogenic mutations, while score value less than 0.5 predicts likely benign mutations.
Statistical methods
Kolmogorov-Smirnov test was performed to examine the normality of parameter distribution. Results of continuous variables were expressed as median and range.
The significance of differences in continuous variables was tested by Mann-Whitney U test and Kruskal-Wallis test. χ 2 tests were used for differences in category frequencies. Kaplan-Meier survival curves were used to illustrate the difference in the time to the manifestation of first thrombotic event among the different AT deficiency types. A p-value of 0.05 or less was considered to indicate statistical significance. All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS 22.0), Chicago IL, USA.
Results
SERPINC1 mutations detected in Antithrombin deficiency
We identified 31 different SERPINC1 mutations (n=22 type I and n=9 type II) with high mutation detection rate (98%) (Fig. 1 ). Among the 31 mutations 11 novel ones were detected (36%). Most of the index patients carried type IIHBS mutations (75.6%) due to the high frequency of the founder ATBp3 (86% out of type IIHBS).
ATBp3 was registered in homozygous and heterozygous forms, while all other SERPINC1 mutations were detected only in heterozygous state. AT Basel and AT Padua I were detected in 5 and in 11 families, respectively. Each type IIRS mutation (AT Stockholm, AT Glasgow and p.Ile386Thr) was registered in one family. AT Torino and AT Budapest 5 (type IIPE) were registered in one family and in five families, respectively. Type I deficiency, regardless of the mutation was detected in 25 families.
Only in the case of three patients having borderline hc-anti-FXa AT activity gave both Sanger sequencing and MLPA analysis a negative result. The first patient had 79%, the second patient had 75% and the third patient had 76% hc-anti-FXa activity. All of them had borderline normal AT antigen concentration (0.22, 0.21 and 0.22 g/L, respectively) and acquired AT deficiency was not excluded.
Genotype-phenotype correlations in patients with SERPINC1 mutations
Clinical characteristics of AT deficient patients according to different types are summarized in Table 1 . Detailed description of patients with type I and type II deficiencies are shown in Supplementary Table 1 for known and Table 2 for novel mutations. Except for type IIRS, where all patients were females, there was no significant difference in gender among the different AT deficiency types ( Table 1 ). There was no significant difference in the ratio of patients with FVL or FIIG20210A mutations among the different AT deficient groups and no other 11 inherited thrombophilia was registered in any of our patients (Table 1) . There were no differences in the ratio of patients with acquired risk factors or provoking factors.
Antiphospholipid syndrome was not found in our patients. The number of patients with congenital vascular anomaly was low in all groups.
Due to the high number of patients with type IIHBS deficiency we were able to compare the clinical characteristics among the different subgroups ( Table 1) . As it was expected, the ratio of symptomatic patients was the highest (92.3%) in ATBp3 homozygotes; it was significantly higher than in ATBp3 heterozygotes (p=0.001) and 
Pediatric patients with AT deficiency
In our cohort 32 patients had the first thrombotic episode in childhood (i.e. before the age of 18) (Supplementary Table 2 ). Most of them were of type IIHBS mutants (n=25) and the majority of children (n=18) were homozygous carriers of ATBp3.
There were two peaks of age (0-1 years and 12-18 years) at the time of first thrombotic episode. 
Laboratory phenotype of patients with SERPINC1 mutations
Hc-anti-FXa AT activity and p-anti-FXa activity were low and correlated well in type I deficient patients. AT antigen concentrations were below the lower limit of the reference interval in all cases (Supplementary Table 1A , Table 2 ).
Both hc-anti-FXa activity and p-anti-FXa AT activities were low in all IIRS and IIPE patients and AT antigen levels were all normal (Supplementary Table 1B In our study the hc-anti-FXa assay that was used for diagnosis, gave low AT activity in all type IIHBS cases (100% sensitivity). In the case of AT Basel and AT Padua I the p-anti-FXa activity and AT antigen were within the reference interval in all patients (as expected); the median of p-anti-FXa/hc-anti-FXa ratio was 1.66; range 1.53-2.05 and it was 1.89; range 1.71-2.10, respectively (Supplementary Table 1B) .
However, low p-anti-FXa activity and AT antigen concentration were detected in some patients with ATBp3 (especially homozygotes). The median p-anti-FXa/hc-antiFXa ratio values in heterozygotes and homozygotes were 1.51 (range 1.28-2.11) and 5.60 (range 2.88-8.85), respectively.
The functional assay used for diagnosis was compared to 2 similar (i.e. FXabased in the presence of heparin) commercially available assays ( As it was suggested by our findings and by earlier studies [10, 12], the substrate type (i.e. anti-FIIa or anti-FXa assay) is not the only factor that influences the sensitivity of functional AT assays. Here we investigated the effect of heparin concentration and pH of assay conditions on assay sensitivity in a pilot experiment using our diagnostic assay (Fig. 3) . 
In silico prediction of novel missense mutations
Sequential alignment for AT in human and in different species showed that all the novel missense mutations affected conservative regions (Fig. 4) . The results of the in silico prediction models are summarized in Table 4 . The ATBp3 mutation (p.Leu131Phe) and the AT Cambridge II (p.Ala416Ser) mutation were used as positive controls, since their pathogenicity had been confirmed by different in vitro studies before. All but the p.Leu131Phe mutations were predicted as definitely pathogenic by the methods. Among the novel missense variants the p.Leu205Pro mutation has been already characterized by our group [35, 36] .
Discussion
In our geographic region 31 different SERPINC1 mutations were found and among them 11 were novel. In our cohort type IIHBS AT deficiency (especially ATBp3) was the most frequent. The high mutation detection rate (98%) that is observed in our study may be caused mainly by the high prevalence of the founder ATBp3. In the background of lower mutation detection rates in patients with low AT levels an aberrant N-glycosylation was hypothesized, or mutations in the regulatory sequences of SERPINC1 (eg. c.1-171C>G) were suggested [37] [38] [39] . Among our novel AT variants all mutations except for p.Pro461Thr showed a laboratory phenotype of type I deficiency. AT activity and antigen concentrations were around 50% in these heterozygous individuals, indicating that the mutant AT may not appear in the circulation. The p.Pro461Thr mutation is suggested as a type IIPE variant based on our laboratory results and on a publication, in which the p.Pro461Leu was described [40] .
Concerning the clinical consequences of AT mutations type I deficiency in general was associated with a severe venous thrombotic phenotype in our cohort, except for AT Wobble, in which case no VTE but MI was registered. AT Truro was considered as type IIHBS variant based on an in silico experiment [41] , however, the laboratory phenotype observed in our study and by others [42] suggests a quantitative defect. The biochemical consequences of this mutation therefore would be interesting 16 to study. According to our knowledge, this paper collected one of the highest number of pediatric AT deficient symptomatic patients to date, where the frequency of type IIHBS was the most prevalent. These findings highlight the importance of AT deficiency screening in unprovoked pediatric thrombosis cases especially in populations, where the prevalence of type IIHBS AT deficiency is high. To date no clear recommendations have been published concerning the therapeutic issues (e.g.
the duration of anticoagulation) in AT deficient patients and no sufficient data exist regarding pediatric cases to release a guideline. In our cohort most of the pediatric patients have been put on long-term anticoagulation, however, the risk of bleeding in this special age group must also be considered.
Type IIHBS is an interesting group of AT deficiency, where the clinical and laboratory phenotypes are more heterogeneous and dependent on the specific mutation. ATBp3, AT Padua I and AT Basel associated with not only VTE but also ATE and pregnancy complications were also registered with different frequencies [27, 43, 44] . When the time to the first manifestation of VTE is considered as a measure of clinical severity in our study, it is to be highlighted that type I AT deficiency is more severe than heterozygous IIHBS deficiency, however ATBp3 homozygosity is more severe than type I AT deficiency in this aspect. Within type IIHBS group ATBp3 homozygosity is the most severe and ATBp3 heterozygosity is significantly more severe than AT Padua I. AT Basel and AT Padua I are not significantly different concerning the time to the first manifestation of VTE. When the time to first manifestation of a composite clinical endpoint including not only VTE but also ATE and pregnancy complications is taken into consideration, the severity of type I and type IIHBS heterozygotes do not differ significantly. ATBp3 homozygosity is more severe than type I and type IIHBS heterozygous AT deficiency in this aspect. AT Basel is rather associated with ATE; the highest number of pregnancy complications is detected in AT Padua I. It is interesting, why no homozygous patients with AT Basel and Padua I were found in our study, however, by screening the literature no such patients had been described elsewhere. It is very likely, that at least one reason for not finding homozygous AT Basel or Padua I patients in our study is the relative rarity of these mutations comparing to the frequency of ATBp3. It is also possible, that -due to their severity -AT Basel and Padua I are lethal mutants in homozygous form.
In our cohort n=29 and n=64 asymptomatic carriers were registered upon family screening below the age of 20 and 50, respectively. Since AT deficiency confers the highest absolute VTE risk among inherited thrombophilia, as demonstrated by prospective studies, the proband's family is worthy of screening for causative mutations [45] . It was suggested that the most beneficial consequence of family-screening was to decrease the incidence of provoked VTE in affected individuals by thromboprophylaxis in high-risk situations and to avoid oral
It is interesting that there are big differences in the sensitivity even among hc- This results in different behavior in the functional assays. Assay modifications, that were tested, had less effect on AT activity values of ATBp3 samples, which suggest more complex consequence of this mutation than being a heparin-binding defect.
Conclusion
In conclusion, in our large group of AT deficient patients it was possible to investigate the mutation detection rate, the genotype-phenotype associations and to explore the behavior of different types of AT deficiency using three different functional assays. Since AT deficiency belongs to the group of rare diseases it is hardly possible to conduct large clinical studies concerning this disease. In our tertiary hemostasis center by a collection of AT deficient patients during a 10-year period we have described 11 novel causative mutations and described the highest SERPINC1 
Conflict of interest
The authors state that they have no conflict of interest. Nucleotide numbering is given to the first nucleic acid of the initiator ATG codon.
Mutations are described according to Human Genome Variation Society guidelines.
Novel mutations are indicated in Bold and Italic style. 
